GlassScriptPhysician profile
Stefanie Gallagher
NPI 1780145755
$2,219.57
in general payments reported to CMS, 2019-2025
19 companies · $881 in 2025
The $881 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $128 · 2021: $152 · 2022: $120 · 2023: $417 · 2024: $521 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,023.08 | 2020-2025 | |
| Daiichi Sankyo INC. | $241.08 | 2024-2025 | Injectafer |
| Ardelyx, INC. | $143.60 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $142.88 | 2021-2025 | Tagrisso |
| Madrigal Pharmaceuticals | $121.85 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $119.99 | 2023 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.94 | 2024-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $44.50 | 2025 | |
| Pfizer INC. | $44.33 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $39.61 | 2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $37.43 | 2024-2025 | Terlivaz |
| Celgene Corporation | $34.43 | 2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $32.17 | 2024-2025 | Tremfya |
| Exact Sciences Corporation | $32.10 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $23.85 | 2023 | Resolution 360 Clip |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $21.66 | 2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $18.80 | 2023 | Entyvio |
| Merck Sharp & Dohme LLC | $17.99 | 2024 | Dificid |
| Medtronic, INC. | $15.28 | 2024 | Nexpowder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.